The drug maker on Tuesday (30 June) launched the Indian branded generic of Axitinib, an tyrosine kinase inhibitor drug with a brand name Axishil.

Axishil is available as 1 mg & 5 mg tablets in pack of 14 tablets in one bottle. It is used to treat patients suffering from advanced renal cell carcinoma (RCC). Currently the monthly therapy cost of innovator is approximately Rs 1.66 lakh and with the launch of Axishil, monthly cost of treatment will be reduced to Rs 14,940.

Axishil is being launched to provide global quality Indian Brand with greater affordability to cancer patients. Today there are around 17,000 to 21,000 new patients in India who needs Axitinib and can be benefited by Axishil tablets, said Sundeip Bhatia, business head formulations India.

Shilpa Medicare is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates.

The drug maker's consolidated net profit surged 248.7% to Rs 55.06 crore on 36.6% jump in net sales to Rs 236.85 crore in Q3 December 2019 over Q3 December 2018.

Powered by Capital Market - Live News

Shilpa Medicare launched the Indian branded generic of Axitinib, an tyrosine kinase inhibitor drug with a brand name AXISHIL.

AXISHIL is available as 1 mg & 5 mg tablets in pack of 14's tablets in onebottle.

AXISHIL is used to treat patients suffering from Advanced Renal CellCarcinoma (RCC).

This novel targeted therapy attacks cancer cells without damaging normalcells, thus causing fewer side effects. There has been a_ significantimprovement in survival rates in patients with advanced renal cancer due to advent of this novel targeted therapy.

Currently the monthly therapy cost of innovator is approximately Rs 1.66 lakh and with the launch of AXISHIL, monthly cost of treatment will be reduced drastically to Rs 14940/-. drastically to Rs. 14940/-.

Powered by Capital Market - Live News

The Board of Shilpa Medicare at its meeting held on 15 June 2020 has approved the acquisition of 100% stake in FTF Pharma for a consideration of Rs 75 crore and 40% stake in Auxilla Pharmaceuticals and Research for Rs 6 crore.

Powered by Capital Market - Live News

Net profit of Shilpa Medicare rose 44.77% to Rs 34.57 crore in the quarter ended March 2020 as against Rs 23.88 crore during the previous quarter ended March 2019. Sales rose 10.26% to Rs 219.99 crore in the quarter ended March 2020 as against Rs 199.52 crore during the previous quarter ended March 2019.

For the full year,net profit rose 39.10% to Rs 156.15 crore in the year ended March 2020 as against Rs 112.26 crore during the previous year ended March 2019. Sales rose 23.80% to Rs 907.91 crore in the year ended March 2020 as against Rs 733.39 crore during the previous year ended March 2019.

Powered by Capital Market - Live News